All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sarconeos
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co., LLC
Deal Size: $6.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 03, 2020
Details:
Net proceeds of the private placement will be used primarily to progress Biophytis drug development programs, including the COVA clinical study, To begin Sarconeos (BIO101) Phase 2/3 clinical trial as a potential treatment for respiratory failure associated with COVID-19.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
